Diaceutics’ (DXRX) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Diaceutics (LON:DXRX) in a research report released on Wednesday morning,Digital Look reports. The brokerage currently has a GBX 215 price objective on the stock.

Diaceutics Trading Up 5.1%

Shares of LON:DXRX opened at GBX 143.50 on Wednesday. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85. Diaceutics has a 52-week low of GBX 125 and a 52-week high of GBX 180. The stock has a market cap of £121.44 million, a price-to-earnings ratio of 1,304.55 and a beta of 0.89. The business has a 50-day moving average price of GBX 141.76 and a 200-day moving average price of GBX 153.29.

Diaceutics (LON:DXRX) last issued its earnings results on Tuesday, May 26th. The company reported GBX 11 EPS for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.The firm had revenue of GBX 3,844 million for the quarter. Equities analysts predict that Diaceutics will post 1.0107919 EPS for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.